U.S. biotech bloodbath hits hedge funds but some bargains emerge
September 29, 2015 at 17:14 PM EDT
Sept 29 (Reuters) - A seven-day selloff of U.S. biotechnology stocks has hit sector investors - especially hedge funds - hard. But some managers say it was overdone and are already eyeing bargains such as Gilead Sciences Inc and Amgen Inc.